Adaptimmune

Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Type
Public
HQ
Philadelphia, US
Founded
2008
Size (employees)
173 (est)
Adaptimmune was founded in 2008 and is headquartered in Philadelphia, US

Adaptimmune Office Locations

Adaptimmune has offices in Philadelphia and Milton
Philadelphia, US (HQ)
2010 Market St
Milton, GB
Park House Park Dr

Adaptimmune Data and Metrics

Adaptimmune Financial Metrics

Adaptimmune's revenue was reported to be $2.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

2.9 m

EBIT (Q1, 2017)

(22.2 m)

Market capitalization (25-Jul-2017)

2.4 b

Cash (31-Mar-2017)

170.6 m
Adaptimmune's current market capitalization is $2.4 b.
USDFY, 2016

Revenue

9 m

R&D expense

(25.5 m)

General and administrative expense

(9.9 m)

Operating expense total

(35.4 m)

EBIT

(26.4 m)

EBIT margin, %

(294%)

Interest income

489 k

Pre tax profit

(23.1 m)

Income tax expense

55 k

Net Income

(23 m)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.9 m328 k2.4 m2.9 m

R&D expense

(13.9 m)(16.2 m)(15.6 m)(18.6 m)

General and administrative expense

(5.9 m)(6.8 m)(5.4 m)(6.5 m)

Operating expense total

(19.7 m)(23 m)(21 m)(25.1 m)

EBIT

(16.8 m)(22.7 m)(18.6 m)(22.2 m)

EBIT margin, %

(577%)(6921%)(771%)(778%)

Interest income

259 k291 k289 k240 k

Pre tax profit

(15.5 m)(21.8 m)(18.4 m)(21.6 m)

Income tax expense

(59 k)(293 k)(104 k)(231 k)

Net Income

(15.6 m)(22.1 m)(18.5 m)
USDFY, 2016

Cash

158.8 m

Accounts Receivable

149.5 k

Inventories

1.4 m

Current Assets

198.8 m

PP&E

27.9 m

Total Assets

234.5 m

Accounts Payable

11.4 m

Current Liabilities

40.3 m

Total Liabilities

68.4 m

Additional Paid-in Capital

341.2 m

Retained Earnings

(161.5 m)

Total Equity

166.1 m

Financial Leverage

1.4 x
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

163.8 m150.9 m140.4 m170.6 m

Current Assets

238.6 m218.2 m199.5 m222.9 m

PP&E

13.8 m13.4 m15.1 m35.1 m

Total Assets

261.6 m239.6 m222.6 m266 m

Accounts Payable

2.4 m2.5 m3.2 m5.2 m

Current Liabilities

19.8 m20.1 m22.7 m31.9 m

Additional Paid-in Capital

334.4 m336.9 m339.2 m405.2 m

Retained Earnings

(105.5 m)(127.6 m)(146.1 m)(183.3 m)

Total Equity

218.9 m197 m180 m208.3 m

Financial Leverage

1.2 x1.2 x1.2 x1.3 x
USDFY, 2016

Net Income

(23 m)

Cash From Operating Activities

(48.2 m)

Cash From Investing Activities

17.8 m

Cash From Financing Activities

17 k
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.6 m)(22.1 m)(18.5 m)

Accounts Payable

2.4 m2.5 m3.2 m5.2 m
USDY, 2017

Revenue/Employee

16.5 k

Financial Leverage

1.3 x

Adaptimmune Operating Metrics

Adaptimmune's Patent Applications was reported to be 69 in FY, 2016
FY, 2016

Patents Issued

173

Patent Applications

69

Adaptimmune Market Value History

Adaptimmune Online and Social Media Presence

Adaptimmune News and Updates

Adaptimmune Company Life and Culture

You may also be interested in